Evidence map›Paper›PMID 40497800›Full record

ArticleACS biomaterials science & engineering2025

Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression.

Maiara Callegaro Velho, Valeria Luiza Winck, Camila da Silveira Mariot, Juliete Nathali Scholl, Augusto Ferreira Weber, Rita de Kássia Souza, Fernanda Visioli, Fabrício Figueiró, Monique Deon, Diogo André Pilger and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maiara Callegaro VelhoPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul (RS) 90620-170, Brazil.
Valeria Luiza WinckLaboratório de Nanocarreadores e Impressão 3D em Tecnologia Farmacêutica (Nano3D), Faculdade de Farmácia - UFRGS, Porto Alegre, RS 90620-170, Brazil.
Camila da Silveira MariotPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul (RS) 90620-170, Brazil.
Juliete Nathali SchollLaboratório de Imunobioquímica do Câncer (LIBC), Departamento de Bioquímica - UFRGS, Porto Alegre, RS 90620-170, Brazil.
Augusto Ferreira WeberLaboratório de Imunobioquímica do Câncer (LIBC), Departamento de Bioquímica - UFRGS, Porto Alegre, RS 90620-170, Brazil.
Rita de Kássia SouzaPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde - UFRGS, Porto Alegre, RS 90620-170, Brazil.
Fernanda VisioliPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde - UFRGS, Porto Alegre, RS 90620-170, Brazil.
Fabrício FigueiróLaboratório de Imunobioquímica do Câncer (LIBC), Departamento de Bioquímica - UFRGS, Porto Alegre, RS 90620-170, Brazil.
Monique DeonLaboratório de Nanocarreadores e Impressão 3D em Tecnologia Farmacêutica (Nano3D), Faculdade de Farmácia - UFRGS, Porto Alegre, RS 90620-170, Brazil.ORCID 0000-0002-9889-7420
Diogo André PilgerPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul (RS) 90620-170, Brazil.ORCID 0000-0002-6773-6480
Ruy Carlos Ruver BeckPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul (RS) 90620-170, Brazil.ORCID 0000-0001-6262-1097

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma presents significant challenges in neuro-oncology due to its aggressive nature, drug resistance, and restrictions imposed by the blood-brain barrier. Ivermectin (IVM), known for its antiparasitic properties, has been highlighted as a promising treatment for tumors and an alternative therapy for glioma, although it exhibits low oral bioavailability. Therefore, we investigated the

Indexed as

Antineoplastic AgentsBrain NeoplasmsGliomaIvermectinNanocapsulesAdministration, IntranasalAnimalsCell Line, TumorCell SurvivalDrug CarriersHumansMalePolyestersRatsRats, WistarSilicon DioxideAntineoplastic AgentsDrug CarriersIvermectinMCM-41NanocapsulesPolyestersSilicon Dioxidecancerglioblastomaivermectinmesoporous silicananocapsulesnose-brain

Identifiers

PMID40497800
PMCPMC12264859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.